Mankind Pharma Sees Sharp Open Interest Surge Amid Bullish Market Positioning

Open Interest and Volume Dynamics

On 7 January 2026, Mankind Pharma Ltd (symbol: MANKIND) recorded a substantial increase in open interest (OI) in its futures and options contracts. The latest OI stood at 14,720 contracts, up by 1,672 contracts or 12.81% from the previous day’s 13,048. This rise in OI accompanied a volume of 12,346 contracts, indicating robust trading activity and heightened market participation.

The futures value traded was approximately ₹12,237.97 lakhs, while the options segment saw an enormous notional value of ₹5,197.09 crores, culminating in a total derivatives turnover of ₹13,286.28 lakhs. The underlying stock price closed at ₹2,286, reflecting a 2.15% gain on the day.

Price Performance and Moving Averages

Mankind Pharma has been on a positive trajectory, gaining 4.34% over the last two consecutive trading sessions. The stock outperformed its Pharmaceuticals & Biotechnology sector by 1.63% and the Sensex by a significant margin, which declined by 0.13% on the same day. Intraday, the stock touched a high of ₹2,291.20, marking a 2.25% increase from the previous close.

Technically, the stock is trading above its 5-day, 20-day, and 50-day moving averages, signalling short- to medium-term bullish momentum. However, it remains below the 100-day and 200-day moving averages, suggesting that longer-term resistance levels are yet to be breached. This mixed technical picture indicates cautious optimism among traders and investors.

Investor Participation and Liquidity

Investor participation has notably increased, with delivery volumes on 6 January reaching 1.79 lakh shares, a sharp 79.24% rise compared to the five-day average delivery volume. This surge in delivery volume suggests that investors are not merely trading intraday but are willing to hold positions, reflecting confidence in the stock’s near-term prospects.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹0.81 crore based on 2% of the five-day average traded value. This liquidity profile is favourable for institutional investors and large traders seeking to build or unwind positions without significant market impact.

Market Positioning and Directional Bets

The surge in open interest alongside rising volumes and price gains suggests that market participants are positioning for a potential upward move in Mankind Pharma’s stock. The 12.81% increase in OI is significant, indicating fresh long positions or rollovers of existing contracts rather than unwinding of positions.

Given the stock’s outperformance relative to its sector and the broader market, traders appear to be betting on continued momentum. The rising delivery volumes reinforce this view, as investors are increasingly willing to take ownership rather than engage in speculative intraday trades.

However, the downgrade in the Mojo Grade from Hold to Sell on 19 November 2025, with a current Mojo Score of 44.0, signals caution. The downgrade reflects concerns over valuation or near-term fundamentals, which may temper overly bullish sentiment. The Market Cap Grade of 1 further suggests that despite its large-cap status with a market capitalisation of ₹92,811 crore, the stock’s quality metrics are currently weak.

Comparative Analysis and Sector Context

Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma’s recent price gains and open interest surge stand out against a sector return of just 0.49% on the same day. This relative strength may attract momentum traders and short-term investors seeking alpha in a defensive sector.

Nonetheless, investors should weigh the positive technical signals against the fundamental caution implied by the Mojo downgrade. The stock’s position below the 100-day and 200-day moving averages suggests that longer-term resistance remains a hurdle, and any sustained rally will require confirmation through improved fundamentals or sector tailwinds.

Implications for Investors

For investors and traders, the recent open interest surge in Mankind Pharma’s derivatives signals a growing conviction in the stock’s near-term upside potential. The combination of rising volumes, increasing delivery participation, and price outperformance relative to sector and benchmark indices supports a cautiously optimistic outlook.

However, the downgrade in the Mojo Grade and the stock’s position below key long-term moving averages counsel prudence. Investors should monitor upcoming quarterly results, sector developments, and broader market trends to validate the sustainability of the current momentum.

Active traders may consider leveraging the increased liquidity and volatility to capitalise on short-term directional moves, while long-term investors might await clearer fundamental improvements before committing fresh capital.

Summary

Mankind Pharma Ltd’s derivatives market activity reveals a significant increase in open interest and volume, reflecting heightened market interest and potential bullish positioning. The stock’s recent price gains and delivery volume surge further underscore positive investor sentiment. Yet, fundamental caution remains due to a recent downgrade in quality ratings and resistance at longer-term moving averages. Investors should balance these factors carefully when considering exposure to this large-cap pharmaceutical player.

Unlock special upgrade rates for a limited period. Start Saving Now →